New Enterprise Associates 17, L.P.
CIK: 0001768564
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (16 total)
- Mar 10, 2026KRRO
Korro Bio, Inc.
Purchase(P)Direct207.1K shares at avg. $11.11$2.3M - Feb 9, 2026SGP
SpyGlass Pharma, Inc.
Conversion(C)Direct1.6M shares- - Feb 9, 2026SGP
SpyGlass Pharma, Inc.
Conversion(C)Direct1.4M shares- - Feb 9, 2026SGP
SpyGlass Pharma, Inc.
Conversion(C)Direct1.4M shares- - Feb 9, 2026SGP
SpyGlass Pharma, Inc.
Conversion(C)Direct738K shares- - Feb 9, 2026SGP
SpyGlass Pharma, Inc.
Purchase(P)Direct937.5K shares at avg. $16.00$15.0M - Oct 2, 2025NEUE
NeueHealth, Inc.
Award(A)DirectWarrant (Right to Buy)
186.1K shares- - Oct 2, 2025NEUE
NeueHealth, Inc.
Sale(S)Direct280 shares at avg. $6.75$2K - Oct 2, 2025NEUE
NeueHealth, Inc.
Exercise(M)Direct186.1K shares at avg. $0.01$2K - Oct 2, 2025NEUE
NeueHealth, Inc.
Tax Payment(F)Direct276 shares at avg. $6.75$2K - Oct 2, 2025NEUE
NeueHealth, Inc.
Disposition(D)Direct674.6K shares- - Oct 2, 2025NEUE
NeueHealth, Inc.
In-the-Money(X)Direct189.2K shares at avg. $0.01$2K - Oct 1, 2024NEUE
NeueHealth, Inc.
Purchase(P)DirectWarrant (Right to Buy)
61.9K shares- - Sep 16, 2024MBX
MBX Biosciences, Inc.
Conversion(C)Direct2.1M shares- - Sep 16, 2024MBX
MBX Biosciences, Inc.
Purchase(P)Direct500K shares at avg. $16.00$8.0M - Sep 16, 2024MBX
MBX Biosciences, Inc.
Conversion(C)Direct1M shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Mar 10, 2026 |  KRRO Korro Bio, Inc. | Purchase(P) | 207,100 | $11.11 | $2,300,881 | Direct |
| Feb 9, 2026 |  SGP SpyGlass Pharma, Inc. | Conversion(C) | 1,619,240 | - | $0 | Direct |
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | Conversion(C) | 1,370,168 | - | $0 | Direct |
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | Conversion(C) | 1,370,168 | - | $0 | Direct |
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | Conversion(C) | 737,962 | - | $0 | Direct |
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | Purchase(P) | 937,500 | $16.00 | $15,000,000 | Direct |
| Oct 2, 2025 |  NEUE NeueHealth, Inc. | Award(A) Warrant (Right to Buy) | 186,128 | - | - | Direct |
| Oct 2, 2025 | NEUE NeueHealth, Inc. | Sale(S) | 280 | $6.75 | $1,890 | Direct |
| Oct 2, 2025 | NEUE NeueHealth, Inc. | Exercise(M) | 186,128 | $0.01 | $1,861 | Direct |
| Oct 2, 2025 | NEUE NeueHealth, Inc. | Tax Payment(F) | 276 | $6.75 | $1,863 | Direct |
| Oct 2, 2025 | NEUE NeueHealth, Inc. | Disposition(D) | 674,554 | - | - | Direct |
| Oct 2, 2025 | NEUE NeueHealth, Inc. | In-the-Money(X) | 189,195 | $0.01 | $1,892 | Direct |
| Oct 1, 2024 | NEUE NeueHealth, Inc. | Purchase(P) Warrant (Right to Buy) | 61,865 | - | - | Direct |
| Sep 16, 2024 |  MBX MBX Biosciences, Inc. | Conversion(C) | 2,091,383 | - | $0 | Direct |
| Sep 16, 2024 | MBX MBX Biosciences, Inc. | Purchase(P) | 500,000 | $16.00 | $8,000,000 | Direct |
| Sep 16, 2024 | MBX MBX Biosciences, Inc. | Conversion(C) | 1,023,103 | - | $0 | Direct |
1-16 of 16 transactions
About New Enterprise Associates 17, L.P.
New Enterprise Associates 17, L.P. (SEC CIK 0001768564) files insider reports with the SEC as 10% Owner of Korro Bio, Inc. (KRRO), 10% Owner of SpyGlass Pharma, Inc. (SGP) and 10% Owner of NeueHealth, Inc. (NEUE). Signal8 also holds filings tied to 1 other company.
Signal8 holds 7 ownership filings by New Enterprise Associates 17, L.P. (2 Form 3, 5 Form 4), filed between Sep 12, 2024 and Mar 12, 2026. Those filings report 16 transactions, from Sep 16, 2024 to Mar 10, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on New Enterprise Associates 17, L.P.'s filings is in TIMONIUM, MD.
Recent filings by New Enterprise Associates 17, L.P.
- Mar 10, 2026: Open-market purchase of KRRO shares (Form 4, code P).
- Feb 9, 2026: Conversions of SGP shares (4 lines, Form 4, code C).
- Feb 9, 2026: Open-market purchase of SGP shares (Form 4, code P).
- Oct 2, 2025: Grant or award of NEUE derivative securities (Form 4, code A).
- Oct 2, 2025: Open-market sale of NEUE shares (Form 4, code S).
Other insiders filing for Korro Bio, Inc. (KRRO)
- Lynx1 Capital Management LP, 10% Owner
- FORMELA JEAN FRANCOIS, Director
- Dolan Oliver, Senior Vice President, Finance
- Aiyar Ram, President and CEO
- Vincent Loic A, Chief Scientific Officer
- Cerio Jeffrey, General Counsel